€240M Boost: AMBOSS Expands Global Healthcare Platform
Founders of AMBOSS: Madjid Salimi (CEO), Benedikt Hochkirchen (CEO), Nawid Salimi (CMedO) - © AMBOSS
In a significant milestone for medical technology, AMBOSS has closed a €240 million financing round, signaling strong investor confidence in its mission to empower healthcare professionals worldwide. According to the company's press release, this substantial investment will drive international expansion and technological innovation.
The financing round, led by prominent investors including KIRKBI, M&G Investments, and Lightrock, marks a strategic moment for the Berlin and New York-based medical knowledge platform. AMBOSS has transformed from a startup to a global resource, now trusted by over 1 million users across 180 countries.
Co-founder Benedikt Hochkirchen emphasized the strategic importance of selecting investors committed to the company's long-term vision. The fresh capital will fuel investments in technology, explore new market segments, and potentially support selective acquisitions, following recent strategic moves like acquiring Novaheal and NEJM Knowledge+.
AMBOSS's unique approach combines medical expertise with cutting-edge AI technology, providing physicians with precise, actionable recommendations. The platform's impact is already notable: every second inpatient treatment in Germany involves a physician supported by AMBOSS, and 25% of first-year US residents rely on the platform for patient care.
Dr. Madjid Salimi, co-founder, articulates the company's philosophy succinctly: "Technology will not replace healthcare professionals, but those who embrace it will lead the way."
